An evaluation of predictive factors involved in clinical or pathological response to primary chemotherapy in advanced breast cancer

Breast Cancer

Volumn 9, Issue 2, 2002, Pages 145-152

  Nishimura, Reiki ^a   Nagao, Kazuharu ^a   Miyayama, Haruhiko ^a   Matsuda, Masakazu ^a   Baba, Ken Ichirou ^a   Matsuoka, Yukio ^a   Yamashita, Hiroya ^a   Fukuda, Makoto ^a  

^a Kumamoto Cily Hospital   (Japan)

Author keywords

Breast cancer; Extensive intraductal component; Primary chemotherapy; Proliferative activity

Indexed keywords

ANTINEOPLASTIC AGENT; CEF REGIMEN; CYCLOPHOSPHAMIDE; CYTARABINE; EPIRUBICIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER INVASION; CANCER STAGING; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; EVALUATION; FEMALE; FOLLOW UP; HUMAN; METHODOLOGY; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PROBABILITY; PROGNOSIS; SEGMENTAL MASTECTOMY; STATISTICAL MODEL; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036359589     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967579     Document Type: Article

References (23)

1. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998. (Pubitemid 28363030)
2. Nishimura R, Nagao K, Miyayama H, et al: Predictive value of proliferative activity for response to chemotherapy or endocrine therapy in advanced or recurrent breast cancer. Jpn J Breast Cancer 12:219-224, 1997 (in Japanese with English abstract).
3. Nishimura R, Nagao K, Miyayama H, et al: Studies on relationships between the effect and prognosis in chemo-endocrine therapy as a first- or second-line treatment for advanced or recurrent breast cancer. Jpn J Breast Cancer 15:309-316, 2000 (in Japanese with English abstract).
4. Paik S, Bryant J, Park C, et al: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negafive breast cancer. J Natl Cancer Inst 18:1361-1370, 1998. (Pubitemid 28439960)
5. Nishimura R, Nagao K, Miyayama H: Studies on Correlation of Positive Surgical Margin with Clinicopathological Factors and Prognoses in Breast Conserving Surgery. Jpn J Breast Cancer 14:219-224, 1999 (in Japanese with English abstract).
6. Japan Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer, 14th ed, Kanehara Publications, Tokyo, 1998 (in Japanese).
7. Committee for Production of Histopathological Criteria, Japanese Breast Cancer Society (chairman: Kurosumi M). Histopathological criteria for assessment of therapeutic response in breast cancer. Breast Cancer 8:1-2, 2001.
8. Bloom HJG and Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11:359 377, 1957.
9. Schnitt SJ, Connolly JL, Harris JR, et al: Pathologic predictors of early local recurrence in stage I and II breast cancer treated by primary radiation therapy. Cancer 53:1049-1057, 1984. (Pubitemid 14196481)
10. Nishimura R, Nagao K, Miyayama H, et al: Evaluation of DNA polymerase a as a prognostic predictor in early breast cancer smaller than 2 cm. Breast Cancer 2:45-50, 1995.
11. Baltali E, Gunel N, Onat DA, et al: Neoadjuvant chemotherapy in locally advanced breast cancer: a preliminary report. Turkish Oncology Study Group. Tumori 85:483-487, 1999. (Pubitemid 30074596)
12. El-Didi MH, Moneer MM, Khaled HM, et al: Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management. Surg Today 30:249-254, 2000. (Pubitemid 30187218)
13. Billgren AM, Rutqvist LE, Tani E, et al: Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival. Acta Onco138:597-601, 1999. (Pubitemid 29333740)
14. Vargas-Roig LM, Gago FE, Tello O, et al: c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 84:129-134, 1999. (Pubitemid 29133822)
15. Kuerer HM, Newman LA, Smith TL, et al: Singletary SE. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Onco117:460-469, 1999. (Pubitemid 29075229)
16. Chang J, Powles TJ, Allred DC, et al: Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Onco117:3058-3063, 1999. (Pubitemid 29470633)
17. Willsher PC, Pinder SE, Gee JM, et al: C-erbB2 expression predicts response to preoperative chemotherapy for locally advanced breast cancer. Anticancer Res 18:3695-3698, 1998. (Pubitemid 28564249)
18. Aas T, Borresen AL, Geisler S, et al: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2:811-814, 1996. (Pubitemid 26225099)
19. Clahsen PC, van de Velde CJ, Duval C, et al: p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Onco116:470-479, 1998. (Pubitemid 28135588)
20. Nishimura R, Nagao K, Miyayama K, et al: Studies on prognosis and biological characteristics of breast cancer with extensive intraductal component after breastconserving surgery. Jpn J Breast Cancer 11:327-332, 1996 (in Japanese with English abstract).
21. Inaji H, Koyama H, Motomura K, et al Immunohistochemical survey of pS2 expression in intraductal lesions associated with invasive ductal carcinoma of the breast. IntJ Cancer 55:883-886, 1993. (Pubitemid 24005329)
22. Motomura K, Koyama H, Noguchi S, et al: Effect of tamoxifen on pS2 expression in human breast cancers. Oncology 54:424-428, 1997. (Pubitemid 27321122)
23. Freedman G, Fowble B, Hanlon A, et al: Patients with early stage invasive cancer with close or positive margins treated with conservative surgery and radiation have an increased risk of breast recurrence that is delayed by adjuvant systemic therapy. Int J Radiat Oncol Biol Phys 44:1005-1015, 1999. (Pubitemid 29342901)